Bristol widens drug-licensing partnership with Ono

09/21/2011 | Reuters

Bristol-Myers Squibb gained rights to investigational cancer immunotherapy BMS-936558/ONO-4538 in all countries except Taiwan, Japan and South Korea through an expanded agreement with Ono Pharmaceutical. Bristol already had exclusivity in North America. In exchange, Ono gets co-development and -marketing rights in Japan to Orencia, Bristol's rheumatoid arthritis drug.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX